BIT 3.33% 3.1¢ biotron limited

Ann: Significant Immunological Outcomes in BIT225 HIV-1 Trial, page-188

  1. J8
    14,554 Posts.
    lightbulb Created with Sketch. 823
    "They need to measure the level of delay in HIV viral rebound after BIT255 treatment interruption. When are they doing this."

    lol
 
watchlist Created with Sketch. Add BIT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.